Information for Canadians about lecanemab’s initial U.S. FDA approval

This is one of our older articles about lecanemab. Read our most recent article about lecanemab for the latest updates.

On January 6, 2023, the U.S. Food and Drug Administration (FDA) approved the new Alzheimer's drug lecanemab. The drug is also known by its brand name, Leqembi.

The FDA didn’t approve lecanemab using its normal process. Instead, the FDA used what it calls an “accelerated approval pathway” aimed at “serious conditions where there is an unmet medical need.”

In the days since that U.S. FDA approval, we at the Alzheimer Society of Canada have been receiving many questions about lecanemab/Leqembi.

Here are some answers, straight from our dementia research experts.

Lecanemab research – general questions

What does research show so far about lecanemab/Leqembi?

A November New England Journal of Medicine study found that lecanemab “resulted in moderately less decline” of thinking and function in people with early Alzheimer’s disease when compared to a placebo.
Specifically, study researchers found that lecanemab slowed cognitive decline by 27% compared to a placebo over 18 months.
In other words, cognitive decline – that is, thinking and memory getting worse – still did happen in people who took lecanemab. But that decline was statistically slower than in people who took a placebo.
Study researchers also found that lecanemab lowered the amount of amyloid in people’s brain. Amyloid is a protein often connected to Alzheimer’s disease.

What major concerns have emerged about this research on lecanemab/Leqembi?

A December Lancet editorial aimed at “tempering hype and hope” around lecanemab/Leqembi said that the research results so far “might not be clinically meaningful.”
Those editorial writers looked more closely at the cognition test the November study used, called the CDR-SB. The writers pointed out that the total impact of Lecanemab/Leqembi on cognition amounted to “a 0.45-point difference on … an 18-point scale.”
The writers also pointed out that a 0.98 to 1.63 difference in CDR-SB points is what some other scientists say is needed to make a substantial difference in the everyday life of a person with mild cognitive impairment or early Alzheimer’s disease.
In other words, the editorial writers say, “whether lecanemab is the game changer that some have suggested remains to be seen.”

Do researchers think more studies of lecanemab are needed?

Yes. In November, the New England Journal of Medicine’s study researchers called for “longer trials” of the drug to find out whether lecanemab is safe and effective to use in early Alzheimer’s disease.
At least four other major clinical trials are going on right now internationally on lecanemab. Those trials should finish between 2025 and 2027, providing more data about the drug.

Questions on lecanemab targets, methods, costs, side effects and more

Who is lecanemab/Leqembi intended for?

The drug is only approved to be used in people with mild cognitive impairment or mild dementia stage of Alzheimer’s disease.
The drug is not supposed to be used for people at moderate or later stages of Alzheimer’s disease.
This drug is also not supposed to be used for any other form of dementia – only for dementia related to Alzheimer’s disease.

How is lecanemab/Leqembi administered?

This drug is to be taken intravenously twice a month.
This drug will also, as some point out, require frequent brain scans for side-effects monitoring.

What are some of the major side effects of lecanemab/Leqembi?

Major side effects of lecanemab in the latest study included brain swelling in 12.6% of study patients, and brain bleeding in 17.3% of study patients.

I read in Science that some people died while taking lecanemab in the latest drug trial. Is this true?

Yes. The New England Journal of Medicine study from November reports that 6 people died while taking lecanemab – this is slightly less than the 7 people who died taking the placebo.
We at the Alzheimer Society of Canada support full investigations of any and all deaths that occur during any kind of drug trial, whether in the dementia sector or beyond.

How much does lecanemab/Leqembi cost?

One of the drug’s makers, Eisai, has set the price at $26,500 USD a year.

Canada-specific questions about lecanemab

Are any Canadian researchers involved in studies about lecanemab/Leqembi?

Dr. Sharon Cohen of the Toronto Memory Clinic was one of the authors and researchers of the lecanemab study published in the New England Journal of Medicine in November.
Other Canadian sites may also have been involved in the drug trial that led to that study.

Can people in Canada use lecanemab/Leqembi?

A few Canadians have taken or are taking lecanemab/Leqembi as part of experimental drug trials.
In Canada, the drug is not available outside of those experimental drug trials.
There is no news yet about when the drug’s makers, Eisai and Biogen, may be applying for Health Canada approval for lecanemab/Leqembi.
The Alzheimer Society of Canada supports any and all findings Health Canada has had or may have in future about the safety and efficacy of dementia drugs for people living in Canada.

How can I, or someone I know, participate in dementia drug trials and research studies in Canada?

If you or someone you know is interested in participating in a clinical drug trial or clinical treatment trial, there are a few different options.
You can find information about clinical trials internationally at clinicaltrials.gov. Some of these trials will have Canadian sites.
You can also find many Canadian dementia studies, and some clinical trials, to participate in at alzheimer.ca/find-studies.
If you are interested in the Toronto Memory Centre’s involvement in the lecanemab/Leqembi trial, you can visit the centre’s website to see if participation is still possible.
You can also ask your doctor, neurologist or other dementia specialist about trials or studies they might know of or be involved in.

Questions about lecanemab and other drugs

What is the same between aducanumab/Aduhelm – the Alzheimer’s disease drug approved by the US FDA in 2021 – and lecanemab/Leqembi?

Both aducanumab and lecanemab are made by the drug companies Biogen and Eisai.
Both drugs are administered intravenously.
Both drugs use antibodies to try to remove amyloid from the brain.

What is different between aducanumab/Aduhelm – the Alzheimer’s disease drug approved by the US FDA in 2021 – and lecanemab/Leqembi?

A difference is that lecanemab binds most strongly to protofibrils (one of the most toxic forms of amyloid beta) while aducanumab binds most strongly to fibrils.
Another difference is that the results for lecanemab on cognitive outcomes have been moderately positive, while the results for aducanumab have been mixed (one clinical trial showed positive results, and the other didn’t).
Another difference, so far, is that two US House of Representative committees investigated the FDA’s approval of aducanumab/Aduhelm, finding that the FDA’s process with drug maker Biogen was “rife with irregularities” and protocol breaches. You can read the full congressional report on these concerns on a house committee website.

What else should I know about the field of dementia drug development right now?

There are now more than 200 dementia drugs in development internationally.
A major push in the drug development field is to find drugs that treat underlying causes of dementia, not just dementia symptoms.
Four drugs are approved in Canada to help manage the symptoms of Alzheimer’s disease, and these drugs have been used here for many years for that purpose. You can read about them on our webpage “Medications approved to treat Alzheimer's disease in Canada.”

The Alzheimer Society of Canada will continue to monitor major drug news around dementia as it develops.

If you have any questions about dementia drugs and access to them, contact your regional Alzheimer Society team using the information at alzheimer.ca/find, or reach our national information line at info@alzheimer.ca or 1-855-705-4636 (INFO).